- Home
- ADT vs PCVX Comparison
ADT vs PCVX Comparison
Compare ADT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADT | PCVX |
|---|---|---|
| Founded | 1874 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.1B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ADT | PCVX |
|---|---|---|
| Price | $8.10 | $49.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $9.25 | ★ $105.00 |
| AVG Volume (30 Days) | ★ 4.4M | 1.1M |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $5,112,859,000.00 | N/A |
| Revenue This Year | $6.12 | N/A |
| Revenue Next Year | $3.60 | N/A |
| P/E Ratio | $10.98 | ★ N/A |
| Revenue Growth | ★ 6.29 | N/A |
| 52 Week Low | $7.24 | $27.66 |
| 52 Week High | $8.94 | $93.77 |
Technical Indicators
Market Signals| Indicator | ADT | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 61.46 |
| Support Level | $7.96 | $44.85 |
| Resistance Level | $8.32 | $48.93 |
| Average True Range (ATR) | 0.14 | 2.39 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 34.18 | 91.74 |
Price Performance
Historical ComparisonAbout ADT ADT Inc.
ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name. The company segments include Consumer and Small Business (CSB).
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.